
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KABP022,KABP023,KABP033
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Zambon Group SpA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB21 (KABP022) formula, consisting of four specific probiotic strains, produces significant positive effects in COVID-19 outpatients, with benefits on remission rate, symptom duration and viral load.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
February 21, 2022
Lead Product(s) : KABP022,KABP023,KABP033
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Zambon Group SpA
Deal Size : Inapplicable
Deal Type : Inapplicable
